Reduction with dithiothreitol causes serglycin-specific defects in secretory granule integrity of bone marrow derived mast cells.
Mast cell granule maturation and storage of granule components has previously been shown to be critically dependent on serglycin (SG), a proteoglycan abundantly stored in mast cell secretory granules. The N-terminal portion of serglycin contains a conserved disulfide motif that is similar to motifs found in secretory granule compounds of neuroendocrine cells. Interference with such motifs of neuroendocrine cells with dithiothreitol (DTT) has previously been shown to cause cellular missorting. To investigate the implication for serglycin, serglycin(+/+) and serglycin(-/-) bone marrow derived mast cells (BMMCs) were treated with DTT followed by assessment of proteoglycan synthesis and secretory granule integrity. Treatment of serglycin(+/+) BMMCs with DTT almost completely abolished biosynthetic incorporation of (35)S-sulfate into proteoglycans, caused a dramatic reduction of granular staining with May Grünwald/Giemsa as well as disruption of granule dense core formation as shown by transmission electron microscopy. In addition, the storage of carboxypeptidase A, a major secretory granule compound, was markedly reduced following DTT treatment. In contrast, none of these effects were seen after treatment of SG(-/-) BMMCs with DTT, indicating that they were serglycin-specific. Notably, DTT treated serglycin(+/+) BMMCs showed similar morphology as did the serglycin(-/-) BMMCs. DTT treatment affected neither the viability of the BMMCs nor the mRNA levels for serglycin or carboxypeptidase A. Together, these data indicate that DTT causes dramatic, serglycin-specific effects on mast cell granule. These findings are thus in accordance with a role for the N-terminal disulfide motif in serglycin for regulation of mast cell secretory granule integrity.
Braga
Tiago
T
Swedish University of Agricultural Sciences, Department of Anatomy, Physiology and Biochemistry, Uppsala, Sweden.
Ringvall
Maria
M
Tveit
Heidi
H
Abrink
Magnus
M
Pejler
Gunnar
G
D000595:Amino Acid Sequence; D000818:Animals; D001854:Bone Marrow Cells / Q000166:cytology* / Q000648:ultrastructure; D048430:Cell Shape / Q000187:drug effects; D004229:Dithiothreitol / Q000494:pharmacology*; D008407:Mast Cells / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism* / Q000648:ultrastructure; D051379:Mice; D008969:Molecular Sequence Data; D010084:Oxidation-Reduction / Q000187:drug effects; D010447:Peptide Hydrolases / Q000378:metabolism; D011509:Proteoglycans / Q000096:biosynthesis / Q000378:metabolism*; D022142:Secretory Vesicles / Q000187:drug effects / Q000473:pathology* / Q000648:ultrastructure; D033921:Vesicular Transport Proteins / Q000096:biosynthesis / Q000378:metabolism*
D011509:Proteoglycans; D033921:Vesicular Transport Proteins; C075430:serglycin; D010447:Peptide Hydrolases; D004229:Dithiothreitol